Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Ofatumumab plus fludarabine and cyclophosphamide meets endpoint in phase III trial in CLL

April 29, 2015

Double-armed oncolytic adenovirus LOAd-703 controls tumor progression

April 29, 2015

EMA classifies NeoStem's NBS-20 as advanced therapeutic medicinal product

April 28, 2015

EMA committee recommends approval of Opdivo for advanced melanoma

April 27, 2015

MedImmune and Juno Therapeutics partner for immuno-oncology clinical trials

April 27, 2015

Celgene and MedImmune collaborate to develop MEDI-4736 for hematologic malignancies

April 24, 2015

Enrollment open in phase II study of GI-6301 for chordoma

April 24, 2015

Ono Pharmaceutical requests squamous NSCLC indication for nivolumab

April 23, 2015

Tolerability, activity of antibody-drug conjugate SAR-408701 encourage clinical development

April 23, 2015

FDA assigns obinutuzumab orphan drug status for follicular lymphoma

April 22, 2015

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...